Health Cytokinetics Unveils Promising Heart Drug Data at ESC25 Cytokinetics has announced that its cardiac myosin inhibitor, aficamten, may redefine the standard of care for patients with heart muscle disorders. This revelation came... Editorial4 days ago
Business HMNC Brain Health Advances Phase 3 Trials for Depression Drug HMNC Brain Health has announced plans to move forward with Phase 3 clinical trials for its depression drug, despite the product’s failure to meet... Editorial5 August, 2025